ATE495441T1 - Verfahren zum testen endokriner substanz in proben - Google Patents

Verfahren zum testen endokriner substanz in proben

Info

Publication number
ATE495441T1
ATE495441T1 AT05809384T AT05809384T ATE495441T1 AT E495441 T1 ATE495441 T1 AT E495441T1 AT 05809384 T AT05809384 T AT 05809384T AT 05809384 T AT05809384 T AT 05809384T AT E495441 T1 ATE495441 T1 AT E495441T1
Authority
AT
Austria
Prior art keywords
analyte
endocrine substance
present
endocrine
measuring
Prior art date
Application number
AT05809384T
Other languages
English (en)
Inventor
Masaaki Kojima
Tatsuyuki Hachisu
Original Assignee
Shibayagi Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shibayagi Co Ltd filed Critical Shibayagi Co Ltd
Application granted granted Critical
Publication of ATE495441T1 publication Critical patent/ATE495441T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/817—Steroids or hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/825—Pretreatment for removal of interfering factors from sample

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Rehabilitation Therapy (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05809384T 2005-06-29 2005-11-22 Verfahren zum testen endokriner substanz in proben ATE495441T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005190003A JP4197180B2 (ja) 2005-06-29 2005-06-29 検体中の内分泌物質測定方法
PCT/JP2005/021443 WO2007000832A1 (ja) 2005-06-29 2005-11-22 検体中の内分泌物質測定方法。

Publications (1)

Publication Number Publication Date
ATE495441T1 true ATE495441T1 (de) 2011-01-15

Family

ID=37595091

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05809384T ATE495441T1 (de) 2005-06-29 2005-11-22 Verfahren zum testen endokriner substanz in proben

Country Status (6)

Country Link
US (1) US8058011B2 (de)
EP (1) EP1898215B1 (de)
JP (1) JP4197180B2 (de)
AT (1) ATE495441T1 (de)
DE (1) DE602005025940D1 (de)
WO (1) WO2007000832A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5413766B2 (ja) * 2008-03-10 2014-02-12 株式会社シバヤギ レプチン測定方法
US20110136141A1 (en) * 2009-12-03 2011-06-09 Abbott Laboratories Peptide reagents and method for inhibiting autoantibody antigen binding
JP5504945B2 (ja) * 2010-02-12 2014-05-28 日東紡績株式会社 Ｆｔｃｄとその自己抗体との複合体の免疫測定方法、それに用いるキット及びそれを用いた癌判定方法
MY192159A (en) * 2015-10-15 2022-08-03 Biocon Ltd Method for detecting neutralizing antibodies against recombinant human insulin in human serum
EP3929584B1 (de) * 2016-09-06 2024-08-14 Fujirebio Inc. Verfahren zur messung von thyreoglobulin
TW201812300A (zh) * 2016-09-13 2018-04-01 日商富士麗比歐股份有限公司 心肌肌鈣蛋白之測定方法及測定試藥
JP7138627B2 (ja) * 2017-05-17 2022-09-16 富士レビオ株式会社 インスリンの測定方法及び測定試薬
WO2018221745A1 (ja) * 2017-06-02 2018-12-06 株式会社Ｌｓｉメディエンス 生体試料中からの標的タンパク質の抽出方法および標的タンパク質の分析方法
CN113631924A (zh) * 2019-05-24 2021-11-09 富士瑞必欧株式会社 甲状腺球蛋白的测定方法和测定试剂
CN111077323A (zh) * 2020-01-12 2020-04-28 天津市宝坻区人民医院 消除胰岛素自身抗体干扰的胰岛素测定试剂盒

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855242A (en) * 1986-04-14 1989-08-08 Joslin Diabetes Center, Inc. Method of detecting antibodies
JPH0291572A (ja) * 1988-09-08 1990-03-30 Nippon Dpc Corp ウァルスｄｎａを用いた生物学的液体中の抗ｄｎａ抗体価の測定法および測定用キット
JPH03134567A (ja) * 1989-10-19 1991-06-07 Yamasa Shoyu Co Ltd 抗リン脂質抗体結合用担体、それを使用する免疫学的測定法およびキット
JP2789306B2 (ja) 1994-11-15 1998-08-20 株式会社第一ラジオアイソトープ研究所 インスリン様成長因子の免疫学的測定方法ならびにインスリン様成長因子測定用キット
JPH11326322A (ja) 1998-05-06 1999-11-26 Shibayagi:Kk イヌインスリン測定用キットおよびそれを用いたイヌインスリン測定方法
JP3740898B2 (ja) * 1998-07-31 2006-02-01 三菱化学株式会社 生理活性成分の測定法
DE69929059T2 (de) 1998-07-31 2006-08-24 Mitsubishi Chemical Corp. Verfahren zum bestimmen von physiologisch aktiven komponenten
WO2003016575A1 (en) * 2001-08-17 2003-02-27 Luminex Corporation Method for characterizing autoimmune disorders
US20050026826A1 (en) * 2003-01-17 2005-02-03 Margarethe Hoenig Feline proinsulin, insulin and constituent peptides

Also Published As

Publication number Publication date
US20090176252A1 (en) 2009-07-09
EP1898215A4 (de) 2008-11-05
JP4197180B2 (ja) 2008-12-17
JP2007010418A (ja) 2007-01-18
EP1898215B1 (de) 2011-01-12
WO2007000832A1 (ja) 2007-01-04
US8058011B2 (en) 2011-11-15
EP1898215A1 (de) 2008-03-12
DE602005025940D1 (de) 2011-02-24

Similar Documents

Publication Publication Date Title
Agapiou et al. Trace detection of endogenous human volatile organic compounds for search, rescue and emergency applications
AR054851A1 (es) Amperometria regulada
DE602007003833D1 (de) Verbesserte vitamin-d-messung
BRPI0814201A2 (pt) Sistema e método de análise de produto de análise em amostra fluida e meio legível em computador
ATE524742T1 (de) Sequenzielle analyse biologischer proben mit zwischenbleichung eines fluoreszenzdetektors
BR112014016158A2 (pt) medições exatas de analito para tira de teste eletroquímica com base na(s) característica(s) física(s) detectada(s) da amostra contendo o analito
ATE520026T1 (de) Sequenzielle analyse biologischer proben
WO2006026020A3 (en) Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
ATE414166T1 (de) Glukosebiosensor und verfahren
CL2011002228A1 (es) Aparato para el analisis integrado de acidos nucleicos en tiempo real, y metodo de detecicion de dichas moleculas.
BRPI0917839A2 (pt) dispositivo de teste de diagnóstico portátil de uso único, e um sistema associado e método para teste de amostras de teste ambientais e biológicas
ATE550642T1 (de) Verfahren zur messung von 1,5-anhydroglucitol in vollblut
WO2007136980A3 (en) Diagnostic test media and methods for the manufacture thereof
BR112022011676A2 (pt) Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método
ATE541216T1 (de) Fluoreszenztestverfahren
ATE370414T1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
ATE495441T1 (de) Verfahren zum testen endokriner substanz in proben
WO2005124356A3 (en) Use of protein cbp2 as a marker for colorectal cancer
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
EP2012116A4 (de) Verfahren und vorrichtung zur individuellen unterscheidung
WO2010000467A8 (en) Asc as a marker for lung cancer
ATE511636T1 (de) Verfahren zum nachweis biologischer organismen mittels raman-streuung
WO2006066917A3 (en) Use of asc as a marker for colorectal cancer
WO2005040806A3 (en) Use of protein asc as a marker for breast cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties